PE20040189A1 - Pirimidina y piridina biciclicos como inhibidores de p38 quinasa - Google Patents

Pirimidina y piridina biciclicos como inhibidores de p38 quinasa

Info

Publication number
PE20040189A1
PE20040189A1 PE2003000209A PE2003000209A PE20040189A1 PE 20040189 A1 PE20040189 A1 PE 20040189A1 PE 2003000209 A PE2003000209 A PE 2003000209A PE 2003000209 A PE2003000209 A PE 2003000209A PE 20040189 A1 PE20040189 A1 PE 20040189A1
Authority
PE
Peru
Prior art keywords
alkyl
pyrimidine
ilamino
tetrahydropyran
aryl
Prior art date
Application number
PE2003000209A
Other languages
English (en)
Inventor
Jian Jeffrey Chen
Christoph Martin Stahl
Nolan James Dewdney
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20040189A1 publication Critical patent/PE20040189A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE PIRIMIDINA Y PIRIDINA AMINO-BICICLICOS 2-SUSTITUIDOS DE FORMULA I DONDE A ES N O CH; R1 ES H, ALQUILO O ARILALQUILO; R2 ES ALQUILO, HIDROXIALQUILO, (R")2NCO-ALQUILENO, CICLOALQUILO, HETEROCICLILO, ARILO, HETEROARILO O HETEROALQUILO; R" ES H O ALQUILO; X ES O, NR3 O S, DONDE R3 ES H, ALQUILO O ARILO; Y ES ENLACE, O, NR', C(=O), CH(R'), CH(OR'), O S(O)n, DONDE n ES 0,1 O 2; R' ES H O ALQUILO; R ES ARILO O HETEROARILO. SON COMPUESTOS PREFERIDOS 2-(TETRAHIDROPIRAN-4-ILAMINO)-6-(2-CLOROBENZOIL)TIENO[2,3-d]PIRIMIDINA; 2-(TETRAHIDROPIRAN-4-ILAMINO)-6-(2-FLUOROBENZOIL)TIENO[2,3-d]PIRIMIDINA; 2-(TETRAHIDROPIRAN-4-ILAMINO)-6-(2-METOXIBENZOIL)-7-METIL-PIRROL[2,3-d]PIRIMIDINA; ENTRE OTROS.TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS SON INHIBIDORES DE LA PROTEINQUINASA p 38 Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE UN TRASTORNO MEDIADO POR PROTEINQUINASA p38 TAL COMO ARTRITIS, ENFERMEDAD DE CROHN, ALZHEIMER, SINDORME DE INTESTINO IRRITABLE, SINDROME DE DISTRESS RESPIRATORIO DEL ADULTO Y ENFERMEDAD OBSTRUCTIVA PULMONAR CRONICA
PE2003000209A 2002-03-07 2003-03-04 Pirimidina y piridina biciclicos como inhibidores de p38 quinasa PE20040189A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36237302P 2002-03-07 2002-03-07
US43050802P 2002-12-03 2002-12-03

Publications (1)

Publication Number Publication Date
PE20040189A1 true PE20040189A1 (es) 2004-05-01

Family

ID=27791709

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000209A PE20040189A1 (es) 2002-03-07 2003-03-04 Pirimidina y piridina biciclicos como inhibidores de p38 quinasa

Country Status (19)

Country Link
US (3) US7091347B2 (es)
EP (1) EP1485390B1 (es)
JP (1) JP4187657B2 (es)
KR (1) KR100714519B1 (es)
CN (1) CN100386328C (es)
AR (1) AR038864A1 (es)
AT (1) ATE410429T1 (es)
AU (1) AU2003210388B2 (es)
BR (1) BR0308232A (es)
CA (1) CA2477721A1 (es)
DE (1) DE60323946D1 (es)
ES (1) ES2314224T3 (es)
MX (1) MXPA04008592A (es)
PA (1) PA8568401A1 (es)
PE (1) PE20040189A1 (es)
PL (1) PL372886A1 (es)
RU (1) RU2301233C2 (es)
TW (1) TW200306194A (es)
WO (1) WO2003074530A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60304718T2 (de) 2002-08-06 2007-04-26 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
US7319102B1 (en) 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
AU2004309420B2 (en) * 2003-12-23 2008-10-30 Novartis Ag Bicyclic heterocyclic p-38 kinase inhibitors
CN1918158B (zh) 2004-02-14 2011-03-02 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
RU2006134022A (ru) 2004-02-27 2008-04-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные индазола и содержащие их фармацевтические композиции
WO2005085249A1 (en) * 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
CN1934111A (zh) * 2004-02-27 2007-03-21 霍夫曼-拉罗奇有限公司 杂芳基稠合的吡唑并衍生物
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
JP5118972B2 (ja) 2004-10-29 2013-01-16 テイボテク・フアーマシユーチカルズ Hiv阻害性二環式ピリミジン誘導体
GB0427604D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
KR101011956B1 (ko) * 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 P38 mαp 키나아제 저해제 및 이의 사용 방법
WO2007124181A2 (en) * 2006-04-21 2007-11-01 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
RU2540074C2 (ru) * 2007-06-21 2015-01-27 Кара Терапеутикс, Инк Производные имидазопиразина или имидазодиазепина, активные в отношении рецептора св2
RU2345996C1 (ru) * 2007-07-17 2009-02-10 Андрей Александрович Иващенко Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения
RU2341527C1 (ru) * 2007-07-17 2008-12-20 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ
PE20091485A1 (es) 2008-02-06 2009-10-26 Novartis Ag DERIVADOS DE PIRROLO-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASAS
TW201002713A (en) 2008-04-09 2010-01-16 Organon Nv Pyrrolo[2,3-d]pyrimidin-2-yl-amine derivatives as PKC-theta inhibitors
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US20130102601A1 (en) * 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
CN103254194B (zh) * 2013-05-17 2015-07-08 浙江师范大学 一种8-硫杂黄嘌呤化合物的制备方法
CN105828822B (zh) 2013-08-14 2019-10-18 诺华股份有限公司 用于治疗癌症的组合疗法
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
US10259816B2 (en) * 2015-04-24 2019-04-16 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
BR112020006677A2 (pt) 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. uso de inibidores p38 para reduzir a expressão de dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
SG11202004971YA (en) * 2017-12-21 2020-06-29 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
US20200339591A1 (en) * 2017-12-21 2020-10-29 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835157A (en) * 1988-03-15 1989-05-30 Ortho Pharmaceutical Corporation Thieno- and furopyrimidine-2,4-dione piperidine derivatives as serotonin antagonists and alpha adrenergic blocking agents
WO1995029897A1 (en) 1994-04-29 1995-11-09 G.D. Searle & Co. METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS
US5834469A (en) 1994-06-09 1998-11-10 Smithkline Beecham Corporation Endothelin receptor antagonists
JPH10510510A (ja) 1994-06-09 1998-10-13 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体拮抗物質
JP3290666B2 (ja) * 1995-06-07 2002-06-10 ファイザー・インコーポレーテッド 複素環式の縮合環ピリミジン誘導体
JP2002514162A (ja) 1996-07-08 2002-05-14 デュポン ファーマシューティカルズ カンパニー Xa因子阻害薬およびトロンビン阻害薬としてのアミジノインドール類、アミジノアゾール類、およびそれらの類似体
JP2001506230A (ja) * 1996-08-09 2001-05-15 スミスクライン・ビーチャム・コーポレイション 新規ピペラジン含有化合物
WO1998008382A1 (en) 1996-08-30 1998-03-05 Eli Lilly And Company Nonclassical pyrrolo[2,3-d]pyrimidine antifolates
BR9812944A (pt) * 1997-10-20 2000-08-08 Hoffmann La Roche Inibidores bicìclicos da cinase
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CA2348740A1 (en) 1998-12-23 2000-07-06 Ruth R. Wexler Thrombin or factor xa inhibitors
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
IL150594A0 (en) 2000-01-07 2003-02-12 Ustav Ex Botan Adademie Ved Ce Purine derivatives, process for their preparation and use
HK1052705B (en) * 2000-08-14 2006-09-29 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazole
AU2002333524A1 (en) * 2001-09-11 2003-03-24 Glaxosmithkline K.K. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors

Also Published As

Publication number Publication date
US20050288312A1 (en) 2005-12-29
TW200306194A (en) 2003-11-16
KR20040091084A (ko) 2004-10-27
US7439247B2 (en) 2008-10-21
WO2003074530A1 (en) 2003-09-12
US7449472B2 (en) 2008-11-11
AR038864A1 (es) 2005-02-02
JP2005526057A (ja) 2005-09-02
US7091347B2 (en) 2006-08-15
US20030207900A1 (en) 2003-11-06
ES2314224T3 (es) 2009-03-16
CN1639168A (zh) 2005-07-13
KR100714519B1 (ko) 2007-05-07
PL372886A1 (en) 2005-08-08
RU2004129768A (ru) 2005-08-27
RU2301233C2 (ru) 2007-06-20
DE60323946D1 (de) 2008-11-20
CN100386328C (zh) 2008-05-07
EP1485390B1 (en) 2008-10-08
ATE410429T1 (de) 2008-10-15
MXPA04008592A (es) 2004-12-06
PA8568401A1 (es) 2003-12-10
AU2003210388B2 (en) 2007-05-17
US20060084803A1 (en) 2006-04-20
CA2477721A1 (en) 2003-09-12
AU2003210388A1 (en) 2003-09-16
EP1485390A1 (en) 2004-12-15
JP4187657B2 (ja) 2008-11-26
BR0308232A (pt) 2004-12-28

Similar Documents

Publication Publication Date Title
PE20040189A1 (es) Pirimidina y piridina biciclicos como inhibidores de p38 quinasa
PE20130012A1 (es) Derivados de pirazol como inhibidores de jak
AU2014233414B2 (en) N-acyl-N'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
PE20030940A1 (es) Derivados de piridina y pirimidina
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
PE20050681A1 (es) PIRIDO[2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
PE20060334A1 (es) Derivados de piridina como antagonistas del receptor a2b de adenosina
KR20210120074A (ko) Jak 억제제 및 그 제조 방법
PE20120224A1 (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
PE20061442A1 (es) Heterociclicos como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia
AU2020279686B2 (en) N-containing heteroaryl derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer
MY136516A (en) Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders, process for their preparation and pharmaceutical compositions containing them
PE20061436A1 (es) Derivados de amida sustituida como inhibidores de proteina quinasa
NO20023218L (no) 2-amino-nikotinamidderivater og deres anvendelse som VEGF- reseptor tyrosinkinaseinhibitorer
PT1261602E (pt) Derivados imidazol-2-carboxamida como inibidores de cinase raf
MX2010008269A (es) Inhibidores de hsp90.
WO2014145029A2 (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
CO5650246A2 (es) Derivados de indazolil(indolil)maleimida sustituidos como inhibidores de cinasa
TW200732329A (en) Aryl-isoxazolo-4-yl-oxadiazole derivatives
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
PE20010912A1 (es) Derivados arilamina y su aplicacion como agentes antitelomerasa
PE20060504A1 (es) Derivados de pirimidina en el tratamiento de cancer
PE20030761A1 (es) Derivados del 7-amino-benzotiazol

Legal Events

Date Code Title Description
FD Application declared void or lapsed